Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program

E. Anders Kolb, Richard Gorlick, Richard Lock, Hernan Carol, Christopher L. Morton, Stephen T. Keir, C. Patrick Reynolds, Min H. Kang, John M. Maris, Catherine Billups, Malcolm A. Smith, Peter J. Houghton

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Background: BMS-754807 is a small molecule ATP-competitive inhibitor of the type-1 insulin-like growth factor receptor currently in phase 1 clinical trials. Procedures: BMS-754807 was tested against the Pediatric Preclinical Testing Program (PPTP) in vitro panel at concentrations ranging from 1.0nM to 10μM and was tested against the PPTP in vivo panels at a dose of 25mg/kg administered orally BID for 6 days, repeated for 6 weeks. Results: In vitro BMS-754807 showed a median EC50 value of 0.62μM against the PPTP cell lines. The median EC50 for the four Ewing sarcoma cell lines was less than that for the remaining PPTP cell lines (0.19μM vs. 0.78μM, P=0.0470). In vivo BMS-754807 induced significant differences in EFS distribution compared to controls in 18 of 32 evaluable solid tumor xenografts (56%) tested, but in none of the ALL xenografts studied. Criteria for intermediate activity for the time to event activity measure (EFS T/C>2) were met in 7 of 27 solid tumor xenografts evaluable for this measure. The best response was PD2 (progressive disease with growth delay), which was observed in 18 of 32 solid tumor xenografts. PD2 responses were most commonly observed in the rhabdomyosarcoma, neuroblastoma, osteosarcoma, Ewing sarcoma, and Wilms tumor panels. Conclusions: BMS-754807 activity in vitro is consistent with a specific IGF-1R effect that has half-maximal response in the 0.1μM range and that is observed in a minority of the PPTP cell lines. In vivo intermediate activity was most commonly observed in the neuroblastoma and rhabdomyosarcoma panels.

Original languageEnglish (US)
Pages (from-to)595-603
Number of pages9
JournalPediatric Blood and Cancer
Volume56
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

IGF Type 1 Receptor
Heterografts
Ewing's Sarcoma
Pediatrics
Cell Line
Rhabdomyosarcoma
Neuroblastoma
Neoplasms
Clinical Trials, Phase I
Wilms Tumor
Osteosarcoma
Adenosine Triphosphate
BMS 754807
Growth
In Vitro Techniques

Keywords

  • Developmental therapeutics
  • IGF-1 receptor inhibitor
  • Preclinical testing

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Kolb, E. A., Gorlick, R., Lock, R., Carol, H., Morton, C. L., Keir, S. T., ... Houghton, P. J. (2011). Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 56(4), 595-603. https://doi.org/10.1002/pbc.22741

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. / Kolb, E. Anders; Gorlick, Richard; Lock, Richard; Carol, Hernan; Morton, Christopher L.; Keir, Stephen T.; Reynolds, C. Patrick; Kang, Min H.; Maris, John M.; Billups, Catherine; Smith, Malcolm A.; Houghton, Peter J.

In: Pediatric Blood and Cancer, Vol. 56, No. 4, 04.2011, p. 595-603.

Research output: Contribution to journalArticle

Kolb, EA, Gorlick, R, Lock, R, Carol, H, Morton, CL, Keir, ST, Reynolds, CP, Kang, MH, Maris, JM, Billups, C, Smith, MA & Houghton, PJ 2011, 'Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 56, no. 4, pp. 595-603. https://doi.org/10.1002/pbc.22741
Kolb, E. Anders ; Gorlick, Richard ; Lock, Richard ; Carol, Hernan ; Morton, Christopher L. ; Keir, Stephen T. ; Reynolds, C. Patrick ; Kang, Min H. ; Maris, John M. ; Billups, Catherine ; Smith, Malcolm A. ; Houghton, Peter J. / Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. In: Pediatric Blood and Cancer. 2011 ; Vol. 56, No. 4. pp. 595-603.
@article{7ac902df1d7f425e91df82da75d24c7a,
title = "Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program",
abstract = "Background: BMS-754807 is a small molecule ATP-competitive inhibitor of the type-1 insulin-like growth factor receptor currently in phase 1 clinical trials. Procedures: BMS-754807 was tested against the Pediatric Preclinical Testing Program (PPTP) in vitro panel at concentrations ranging from 1.0nM to 10μM and was tested against the PPTP in vivo panels at a dose of 25mg/kg administered orally BID for 6 days, repeated for 6 weeks. Results: In vitro BMS-754807 showed a median EC50 value of 0.62μM against the PPTP cell lines. The median EC50 for the four Ewing sarcoma cell lines was less than that for the remaining PPTP cell lines (0.19μM vs. 0.78μM, P=0.0470). In vivo BMS-754807 induced significant differences in EFS distribution compared to controls in 18 of 32 evaluable solid tumor xenografts (56{\%}) tested, but in none of the ALL xenografts studied. Criteria for intermediate activity for the time to event activity measure (EFS T/C>2) were met in 7 of 27 solid tumor xenografts evaluable for this measure. The best response was PD2 (progressive disease with growth delay), which was observed in 18 of 32 solid tumor xenografts. PD2 responses were most commonly observed in the rhabdomyosarcoma, neuroblastoma, osteosarcoma, Ewing sarcoma, and Wilms tumor panels. Conclusions: BMS-754807 activity in vitro is consistent with a specific IGF-1R effect that has half-maximal response in the 0.1μM range and that is observed in a minority of the PPTP cell lines. In vivo intermediate activity was most commonly observed in the neuroblastoma and rhabdomyosarcoma panels.",
keywords = "Developmental therapeutics, IGF-1 receptor inhibitor, Preclinical testing",
author = "Kolb, {E. Anders} and Richard Gorlick and Richard Lock and Hernan Carol and Morton, {Christopher L.} and Keir, {Stephen T.} and Reynolds, {C. Patrick} and Kang, {Min H.} and Maris, {John M.} and Catherine Billups and Smith, {Malcolm A.} and Houghton, {Peter J.}",
year = "2011",
month = "4",
doi = "10.1002/pbc.22741",
language = "English (US)",
volume = "56",
pages = "595--603",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program

AU - Kolb, E. Anders

AU - Gorlick, Richard

AU - Lock, Richard

AU - Carol, Hernan

AU - Morton, Christopher L.

AU - Keir, Stephen T.

AU - Reynolds, C. Patrick

AU - Kang, Min H.

AU - Maris, John M.

AU - Billups, Catherine

AU - Smith, Malcolm A.

AU - Houghton, Peter J.

PY - 2011/4

Y1 - 2011/4

N2 - Background: BMS-754807 is a small molecule ATP-competitive inhibitor of the type-1 insulin-like growth factor receptor currently in phase 1 clinical trials. Procedures: BMS-754807 was tested against the Pediatric Preclinical Testing Program (PPTP) in vitro panel at concentrations ranging from 1.0nM to 10μM and was tested against the PPTP in vivo panels at a dose of 25mg/kg administered orally BID for 6 days, repeated for 6 weeks. Results: In vitro BMS-754807 showed a median EC50 value of 0.62μM against the PPTP cell lines. The median EC50 for the four Ewing sarcoma cell lines was less than that for the remaining PPTP cell lines (0.19μM vs. 0.78μM, P=0.0470). In vivo BMS-754807 induced significant differences in EFS distribution compared to controls in 18 of 32 evaluable solid tumor xenografts (56%) tested, but in none of the ALL xenografts studied. Criteria for intermediate activity for the time to event activity measure (EFS T/C>2) were met in 7 of 27 solid tumor xenografts evaluable for this measure. The best response was PD2 (progressive disease with growth delay), which was observed in 18 of 32 solid tumor xenografts. PD2 responses were most commonly observed in the rhabdomyosarcoma, neuroblastoma, osteosarcoma, Ewing sarcoma, and Wilms tumor panels. Conclusions: BMS-754807 activity in vitro is consistent with a specific IGF-1R effect that has half-maximal response in the 0.1μM range and that is observed in a minority of the PPTP cell lines. In vivo intermediate activity was most commonly observed in the neuroblastoma and rhabdomyosarcoma panels.

AB - Background: BMS-754807 is a small molecule ATP-competitive inhibitor of the type-1 insulin-like growth factor receptor currently in phase 1 clinical trials. Procedures: BMS-754807 was tested against the Pediatric Preclinical Testing Program (PPTP) in vitro panel at concentrations ranging from 1.0nM to 10μM and was tested against the PPTP in vivo panels at a dose of 25mg/kg administered orally BID for 6 days, repeated for 6 weeks. Results: In vitro BMS-754807 showed a median EC50 value of 0.62μM against the PPTP cell lines. The median EC50 for the four Ewing sarcoma cell lines was less than that for the remaining PPTP cell lines (0.19μM vs. 0.78μM, P=0.0470). In vivo BMS-754807 induced significant differences in EFS distribution compared to controls in 18 of 32 evaluable solid tumor xenografts (56%) tested, but in none of the ALL xenografts studied. Criteria for intermediate activity for the time to event activity measure (EFS T/C>2) were met in 7 of 27 solid tumor xenografts evaluable for this measure. The best response was PD2 (progressive disease with growth delay), which was observed in 18 of 32 solid tumor xenografts. PD2 responses were most commonly observed in the rhabdomyosarcoma, neuroblastoma, osteosarcoma, Ewing sarcoma, and Wilms tumor panels. Conclusions: BMS-754807 activity in vitro is consistent with a specific IGF-1R effect that has half-maximal response in the 0.1μM range and that is observed in a minority of the PPTP cell lines. In vivo intermediate activity was most commonly observed in the neuroblastoma and rhabdomyosarcoma panels.

KW - Developmental therapeutics

KW - IGF-1 receptor inhibitor

KW - Preclinical testing

UR - http://www.scopus.com/inward/record.url?scp=79551630554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551630554&partnerID=8YFLogxK

U2 - 10.1002/pbc.22741

DO - 10.1002/pbc.22741

M3 - Article

C2 - 21298745

AN - SCOPUS:79551630554

VL - 56

SP - 595

EP - 603

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -